Global Pharma and Biotech Clinical Stage Partnering Terms and Agreements Report/Directory 2021: Comprehensive Listing of Over 2,600 clinical Stage Partnering Deals Announced Since 2014 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021” report has been added to ResearchAndMarkets.com’s offering.

The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,600 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Why do companies partner clinical stage compounds?

2.1. Introduction

2.2. The role of clinical stage partnering

2.2.1. In-licensing at clinical stage

2.2.2. Out-licensing at clinical stage

2.3. Difference between phase I, II and III stage deals

2.4. Reasons for entering into clinical stage partnering deals

2.4.1. Licensors reasons for entering clinical stage deals

2.4.2. Licensees reasons for entering clinical stage deals

2.5. The future of clinical stage partnering deals

Chapter 3 – Clinical stage deal strategies and structure

3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical/biotech

3.2.1.1. Discovery and preclinical stage partnering case studies

3.2.1.1.a. Case study: LEO Pharma – 4SC

3.2.1.1.b. Case study: Heptares Therapeutics – Cubist

3.2.1.1.c. Case study: Incyte – Agenus Bio

3.2.1.1.d. Case study: Janssen Pharmaceutical – Evotec

3.2.2. Partnering later in pharmaceutical/biotech

3.2.2.1. Clinical stage partnering case studies

3.2.2.1.a. Case study: Servier – GeNeuro

3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals

3.2.2.1.c. Case study: AstraZeneca – Ardelyx

3.2.2.1.d. Case study: Baxter – Onconova Therapeutics

3.3. Early and later stage partnering – a risk/cost comparison

3.4. What do companies spend on clinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure licensing agreements

3.6.1.a. Case study : Argos Therapeutics – Medinet

3.6.1.b. Case study : Pfizer – GlycoMimetics

3.7. Multicomponent clinical stage partnering agreements

3.7.1. Example multicomponent clinical stage clauses

3.7.1.a. Case study: Gilead Sciences – GlobeImmune

Chapter 4 – Clinical stage partnering payment strategies

4.1. Introduction

4.2. Clinical stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments

4.3.2.1. Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments

4.3.9.1. Issues affecting royalty rates

4.3.9.2. Royalties on combination products

4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

4.3.9.3. Guaranteed minimum/maximum annual payments

4.3.9.4. Royalty stacking

4.3.9.5. Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments

Chapter 5 – Trends in clinical stage deal making

5.1. Introduction

5.2. Clinical stage partnering over the years

5.2.1. Trends in phase I deals since 2014

5.2.2. Trends in phase II deals since 2014

5.2.3. Trends in phase III deals since 2014

5.3. Clinical stage partnering by deal type

5.4. Clinical stage partnering by disease type

5.5. Partnering by clinical stage technology type

5.6. Clinical stage partnering by most active company since 2014

Chapter 6 – Payment terms for clinical stage partnering

6.1. Introduction

6.2. Guidelines for clinical stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Clinical stage payment terms – deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Clinical stage partnering headline values

6.4.2. Clinical stage deal upfront payments

6.4.3. Clinical stage deal milestone payments

6.4.4. Clinical stage royalty rates

6.5 Clinical stage median financials

6.5.1. Clinical stage headline value

6.5.2. Clinical stage upfront value

6.5.3. Clinical stage milestone value

6.5.4. Clinical stage royalty value

Chapter 7 – Leading clinical stage deals

7.1. Introduction

7.2. Top clinical stage deals by value

Chapter 8 – Top 25 most active clinical stage dealmakers

8.1. Introduction

8.2. Top 25 most active clinical stage dealmakers

Chapter 9 – Clinical stage partnering contracts directory

9.1. Introduction

9.2. Clinical stage deals with contracts since 2014

Chapter 10 – Clinical stage deal making by development stage

10.1. Introduction

10.2. Deals by clinical stage

Phase I

Phase II

Phase III

Regulatory

Appendices

Appendix 1 – Clinical stage dealmaking by companies A-Z

Appendix 2 – Clinical stage dealmaking by industry sector

Appendix 3 – Clinical stage dealmaking by stage of development

Appendix 4 – Clinical stage dealmaking by therapy area

Appendix 5 – Clinical stage dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/r/ar5u0t

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900